Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
BridgeBio Pharma Inc is a biotechnology business based in the US. BridgeBio Pharma shares (BBIO) are listed on the NASDAQ and all prices are listed in US Dollars. BridgeBio Pharma employs 576 staff and has a trailing 12-month revenue of around $90.7 million.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Active traders
| Latest market close | $10.37 |
|---|---|
| 52-week range | $4.98 - $53.57 |
| 50-day moving average | $10.56 |
| 200-day moving average | $10.86 |
| Wall St. target price | $24.44 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-4.08 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $10.37 from 2022-10-03
| 1 week (2022-09-28) | -3.62% |
|---|---|
| 1 month (2022-09-01) | 1.47% |
| 3 months (2022-07-05) | -3.89% |
| 6 months (2022-04-05) | -14.30% |
| 1 year (2021-10-05) | -77.62% |
|---|---|
| 2 years (2020-10-05) | -73.93% |
| 3 years (2019-10-04) | 19.43 |
| 5 years (2017-10-01) | N/A |
| Revenue TTM | $90.7 million |
|---|---|
| Gross profit TTM | $66.6 million |
| Return on assets TTM | -34.59% |
| Return on equity TTM | -1789.67% |
| Profit margin | 0% |
| Book value | $3.92 |
| Market capitalisation | $1.5 billion |
TTM: trailing 12 months
We're not expecting BridgeBio Pharma to pay a dividend over the next 12 months.
Over the last 12 months, BridgeBio Pharma's shares have ranged in value from as little as $4.98 up to $53.57. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while BridgeBio Pharma's is 0.5886. This would suggest that BridgeBio Pharma's shares are less volatile than average (for this exchange).
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.